<DOC>
	<DOCNO>NCT02115919</DOCNO>
	<brief_summary>Caused human papillomavirus ( HPV ) , anogenital wart common sexually-transmitted infection ( STI ) . They distress source viral shed transmission others . Treatment wart aim destruction lesion . Objectives : 1 . Establish safety Multikine treatment perianal condyloma . 2 . Describe presence anal HPV anal dysplasia participant perianal condyloma . 3 . Describe adverse effect associate Multikine management perianal condyloma . Design : Phase I , dose-escalation trial . Potential participant desire treatment perianal wart refer study primary clinician . All participant undergo baseline anal Pap , anal HPV subtyping , perianal condyloma characterization ( count , measurement , photography ) , complete baseline questionnaire . Cohort A participant undergo perilesional Multikine injection ( 200IU ) daily , Monday Friday , 14 day , 14 day , daily , Monday Friday 14 day . If serious adverse event note 4 week therapy , cohort B study use schedule dose 400IU per treatment . Each participant undergo anal Pap anal HPV subtyping weekly treatment . Condyloma characterization ( count , measurement , photography ) occur prior treatment . After treatment complete , participant complete follow-up visit 70 , 100 , 130 , 160 day anal Pap , anal HPV subtyping , perianal condyloma characterization ( count , measurement , photography ) perform . Subjects : The study open adult men woman HIV-infected receive medical care Naval Medical Center San Diego . Main Outcome Measures : 1 . Perianal wart characterization [ count , measurement ( millimeter diameter ) ] , photography ) 2 . HPV subtype anal canal 3 . Anal dysplasia cytologic grade 4 . Questionnaire responses 5 . Adverse effect experience treatment , record symptom log</brief_summary>
	<brief_title>Safety Study Multikine Treatment Perianal Warts</brief_title>
	<detailed_description>There detail describe regard research project</detailed_description>
	<criteria>â‰¥18 year age Diagnosed perianal condyloma primary clinician HIVinfected , may antiretroviral therapy CD4 count consider appropriate study Blood WBC &gt; 2.0x103/mm3 absolute neutrophil count &gt; 500 Blood hemoglobin &gt; 10.0 g/dL Blood platelet count &gt; 50x103/mm3 Serum total bilirubin &lt; 6.0 mg/dL ( participant take atazanavirbased ARV regimen may elevate total bilirubin generally &lt; 6 ) Blood aspartate aminotransferase ( AST ) &lt; 100 U/L ( &lt; 2 ULN ) Blood alanine aminotransferase ( ALT ) &lt; 130 U/L ( &lt; 2 ULN ) Serum creatinine &lt; 1.5 mg/dL ECOG performance status &lt; 3 If subject reproductive potential he/she her/his sexual partner MUST willing able utilize effective method contraception ( e.g. , birth control pill , barrier method spermicide applicable ) duration study include study followup period . Anal cancer ( current history ) Inability attend study visit Participation drug study History asthma History organ transplantation require chronic administration immune suppressive drug last 6 month For woman , neither pregnant lactating In opinion PI , subject may able tolerate study treatment regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>condyloma</keyword>
	<keyword>HIV</keyword>
</DOC>